DOCSLIB.ORG

Testing for 'Spice' and Everything Nice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Testing for 'Spice' and Everything Nice Testing for ‘Spice’ and Everything Nice Andrew Stolbach, MD March 17, 2016 Objectives List different classes of synthetic cannabinoids Describe commercially available testing modalities for SC drugs Discuss clinical and forensic uses of SC testing Discuss limitations of clinical and forensic SC testing Recap JWH-018, the naphthoylindole synthetic cannabinoid sweeps the world in 2008 Recap United States Drug Laws were not adequate to address the epidemic SC Drugs do not meet strict definition of controlled substance analogs SC drugs were eventually scheduled on emergency, individual basis Cyclohexylphenol SC Structure Core Link Ring Tail Source : EMDCCA Naphthoylindole Naphthylmethylindole Phenylacetylindole Tetramethylcyclopropylindole Adamantylcarboximideindole Adamantylcarboximideindazole Quinolinoylcarboxylateindole Naming of SC Compounds JWH Compounds named after J.W. Huffman Naming of SC Initials of Scientist JWH AM- Compounds Compounds named after named after J.W. Alexander Huffman Makriyannis JW Huffman Alexander Makriyannis Naming of SC Space Shuttle Mission STS-135 Naming of SC Japanese Girl Band AKB-48 Naming of SC Contraction of IUPAC Name N-(1-adamantyl)-1-pentyl-1H- indazole-3-carboxamide = APINACA Non-comprehensive list of SC 5C-MN-24 (5-C-NNEI) ADB-FUBINACA FU-AEB JWH-249 PX-2 (5F-APP-PINACA) FUB-144 (FUB-UR-144) 5F-AB-PINACA ADB-PINACA JWH-250 PX-3 (APP-CHMINACA) FUB-AMB (AMB-FUBINACA) JWH-251 5F-ADB (5F-MDMB-PINACA) ADBICA (ADB-PICA) QUCHIC (BB-22) AM-1220 FUB-APINACA JWH-302 5F-AEB QUPIC (PB-22) AM-1221 FUB-PB-22 JWH-320 5F-AMB RCS-4 AM-1235 FUBIMINA (BIM-2201) JWH-398 5F-APINACA AM-1241 HU-210 JWH-424 RCS-8 5F-JWH-122 (MAM-2201, 4- AM-1248 HU-210 CAS LY-2183240 RCS-8 CAS Methyl-AM-2201) AM-2201 (5F-JWH-018) HU-308 CAS MAM-2201 SDB-005 5F-JWH-210 (EAM-2201, 4- AM-2232 JTE-907 MDA-19 SDB-006 Ethyl-AM-2201) AM-2233 JTE7-31 MDMB-CHMICA STS-135 (5F-APICA) 5F-MN-18 AM-630 (6- JWH-007 (wrongly advertised THJ-018 5F-MN-24 (5F-NNEI) Iodopravadoline) JWH-015 as MMB- CHMINACA) THJ-2201 5F-PCN AM-679 JWH -018 (AM-678) MDMB-CHMINACA UR-144 5F-QUPIC (5F-PB-22) AM-694 JWH-019 MDMB-FUBINACA WIN-48,098 (Pravadoline) 5F-SDB-005 AMB JWH-073 MEPIRAPIM APICA (SDB-001, 2NE1) JWH-081 WIN-55,225 (JWH-200) 5F-SDB-006 MMB-2201 (I-AMB, APINACA (AKB48) JWH-098 XLR-11 (5F-UR-144 CAS) 5F-UR-144 (XLR-11) 5F-AMB-PICA) APP-FUBINACA JWH-116 A-796,260 MN-18 AZ-037 JWH-122 (4-Ethyl-JWH-018) A-834,735 MN-24 (NNE1, BIM-018 JWH-149 A-836,339 NNEI) CB-13 JWH-167 MN-25 AB-001 CP 47,497 JWH-182 Nabilone AB-002 CP 55,940 JWH-193 NESS-0327 AB-005 CP-47,497 JWH-198 NESS-040C5 AB-CHFUPYCA CP-55,940 JWH-200 NM-2201 AB-CHMINACA (MA- EG-018 JWH-200 (WIN-55,225) Org-28611 CHMINACA) FAB-144 JWH-203 Pravadoline (WIN- AB-FUBINACA FDU-PB-22 JWH-210 (4-Methyl-JWH-018) 48,098) AB-PINACA PX-1 (5F-APP-PICA) ADB-CHMINACA (MAB- CHMINACA) Do we test for synthetic cannabinoids? It depends on who you are and which synthetic cannabinoids you are referring to Why We Test Employment-based programs Reasonable suspicion Random Pre-employment Post-accident Legal/Forensic/Postmortem Testing Medical Settings Emergency departments Inpatient medical and psychiatry units Pain management programs Substance abuse treatment programs Department of Transportation Testing Marijuana Cocaine Opiate Amphetamines Phencyclidine metabolites metabolites metabolites (PCP) DOT Rule 49 CFR Part 40 Section 40.85 Department of Defense Testing Marijuana metabolites Cocaine metabolites Amphetamines Opiate metabolites Phencyclidine (PCP) Semi-synthetic opioids Benzodiazepines Synthetic cannabinoids Department of Defense Drug Demand Reduction Program Synthetic Cannabinoid Evolution 2010 2011 2012 2013 2014 JWH-018 AM-2201 JWH-203 PB-22 AB-PINACA JWH-073 AM-694 JWH-022 F-PB-22 AB-FUBINACA JWH-019 JWH-081 JWH-018 Cl-analog BB-22 ADBICA JWH-250 JWH-122 UR-144 MAM-2201 5-F-ADBICA JWH-200 XLR-11 AKB-48 ADB-PINACA JWH-210 AM-2233 F-AKB-48 ADB-FUBINACA RCS-4 AM-1248 5-F-ADB-PINACA RCS-8 A-796260 AB-001 F-AB-001/STR135 APICA PB-22 APINACA/AKB48 EAM-2201 THJ-2201 THJ-018 … Dr. Barry Logan. NMS Labs Positivity – Blood: 2010-2013 Any Analyte 60 Feb 2011: April 2013: JWH-018 NMS BloodJuly 2012: Results US DEA US DEA JWH-073 US DEA JWH-250 Controls Controls XLR- controls JWH-019 JWH-018, 11 and UR- AM-2201, AM-2201 JWH-250 144 JWH-081 45 JWH-122 JWH-122 JWH-210 RCS-4 RCS-8 AM-2233 JWH-022 30 JWH-018 Analog UR-144 % Positive XLR-11 15 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2010 2011 2011 2011 2011 2012 2012 2012 2012 2013 2013 2013 2013 2014 Source: Data extracted from NMS Labs Laboratory Information Management System . October 2010 March 2014. Dr. Barry Logan. NMS Labs Positivity – Blood: 2014-2015 June 2015 Feb 2014: ADB- Dec 2014: CHMINACA US DEA US DEA Controls Controls added to AB-CHMINACA scope PB-22 AB-PINACA 5F-PB-22 THJ-2201 AB- FUBINACA ADB-PINACA Dr. Barry Logan. NMS Labs Staying Current with Synthetic Cannabinoids Seized drug casework Toxicological Casework Government Data/NFLIS Electronic Databases and Subscriptions Peer review literature monitoring Conference proceedings Collaborations with instrument vendors Drug Scheduling actions International conferences and networking Drug user forums, chat rooms and events Field Work Lab work Dr. Barry Logan. NMS Labs Staying Current with SC National Forensic Laboratory Information System DEA Program Collects data from state, local, federal forensic labs 271 Labs throughout the US regularly report data NFLIS Report 2010-13 Immunoassay-Advantages + Sensitive Readily automated Inexpensive Immunoassay-Limitations - Class specific Cross-reactivity is unpredictable Small changes- (length of tail, steric profile of functional group) affect cross-reactivity of the drug Immunoassay may take 9-18 months to develop Different matrices will require different targets Liquid Chromatography/Mass Spectrometry Does not require Can be updated Definitive development of an validated in a new antibodies few days Blood/Serum-Advantages + Quantitative Good for levels may be identifying recent clinically use meaningful Blood/Serum-Limitations - Predominantly Requires targets parent venipuncture compounds Smoked Synthetic Cannabinoids Concentration Urine-Advantages + Less invasive Easier to collect than than venipuncture venipuncture Urine-Limitations - Identifies metabolites- not Substitution parent and compounds (so adulteration you need to know the metabolites Oral Fluid-Advantages + Parent Easy- Indicates recent compound Noninvasive use detectable Oral Fluid-Limitations - Does not indicate chronic use Oral Fluid Collection Expectoration (neat oral fluid) Collection device Cotton collection pads/swabs Cellulose pads Oral Fluid Positivity for JWH-018 and JWH-200 Limit of detection Limit of detection Kneisel S et al. Annals Biochem Hair-Advantages + Provides history of exposure (for Easy- example in child Noninvasive custody or reinstatement of driver’s license) Hair-Limitation Vulnerable to sidestream contamination Commercial Tests-NMS Labs 5F-PB-22 ABCHMINACA AB-FUBINACA AB-PINACA ADB-PINACA ADB-PINACA ADBICA AKB48 BB-22 JWH-018 JWH-073 UR-144 (All metabolites) NMS Labs, Synthetic Cannabinoid Metabolites Screen- Expanded, Urine (forensic) Commercial Tests-Quest AM--2201 JWH-018 JWH-073 JWH-019 JWH-250 (all metabolites) Quest Synthetic Cannabinoid Panel 2, Urine, LC/MS/MS Commercial Tests- ELISA Point of Care (Dipsticks) Can be purchased Often limited online panels How good are these tests? Detection False Sensitivity? Specificity? Interval Positives? Conclusions SC use is Rapidly Evolving We can accurately test for SC in urine, blood, hair, oral fluid We can identify SC shortly after use (oral fluid, blood/serum) and months after use (hair) Testing will not be accurate if we do not test for the drugs our patients are using.
Load more

Recommended publications
  • DEPARTMENT of JUSTICE Drug Enforcement
    This document is scheduled to be published in the Federal Register on 08/03/2021 and available online at DEPARTMENT OF JUSTICEfederalregister.gov/d/2021-16499, and on govinfo.gov Drug Enforcement Administration Bulk Manufacturer of Controlled Substances Application: Cerilliant Corporation [Docket No. DEA-873] AGENCY: Drug Enforcement Administration, Justice. ACTION: Notice of application. SUMMARY: Cerilliant Corporation has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Such persons may also file a written request for a hearing on the application on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. ADDRESS: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on June, 24, 2021, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled Substance Drug Code Schedule 3-Fluoro-N-methylcathinone
    [Show full text]
  • Swedish Code of Statutes
    1. ------IND- 2018 0506 S-- EN- ------ 20190508 --- --- FINAL Swedish Code of Statutes Ordinance amending the Ordinance (1999:58) banning certain products SFS 2018:1587 that are harmful to health Published Issued on 4 October 2018 on 9 October 2018 The Government hereby lays down1 that the annex to the Ordinance (1999:58) prohibiting certain products that are harmful to health shall read as set out below. ___________ This ordinance shall enter into force on 12 November 2018. On behalf of the government ANNIKA STRANDHÄLL Kjell Rempler (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Annex SFS 2018:1587 List of products to be regarded as products that are harmful to health in accordance with the Ordinance prohibiting certain products that are harmful to health N-methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine (MBDB) 1-(3,4-methylenedioxyphenyl)-2-butylamine (BDB) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT) 5-methoxy-alphamethyltryptamine (5-MeO-AMT) 2,5-dimethoxy-4-ethylphenethylamine (2C-E) alpha-methyltryptamine (AMT) 2,5-dimethoxy-4-chlorophenethylamine (2C-C) 2,5-dimethoxy-4-methylphenethylamine (2C-D) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT) gamma-butyrolactone (GBL) 1,4-butanediol (1,4-BD) 4-acetoxy-N,N-methylisopropyltryptamine
    [Show full text]
  • Analysis of Synthetic Cannabinoids and Drugs of Abuse Amongst HIV-Infected Individuals
    City University of New York (CUNY) CUNY Academic Works Student Theses John Jay College of Criminal Justice Fall 12-2016 Analysis of synthetic cannabinoids and drugs of abuse amongst HIV-infected individuals Jillian M. Wetzel CUNY John Jay College, [email protected] How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/jj_etds/2 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] i Analysis of synthetic cannabinoids and drugs of abuse amongst HIV-infected individuals A thesis presented in partial fulfillment of the requirements for the degree of Master of Science in Forensic Science John Jay College of Criminal Justice City University of New York Jillian Wetzel December 2016 ii Analysis of synthetic cannabinoids and drugs of abuse amongst HIV-infected individuals Jillian Michele Wetzel This thesis has been presented to and accepted by the Office of Graduate Studies, John Jay College of Criminal Justice in partial fulfillment of the requirements for the degree of Master of Science in Forensic Science Thesis Committee: Thesis Advisor: Marta Concheiro-Guisan, Ph.D. Second Reader: Shu-Yuan Cheng, Ph.D. External Reader: Richard Curtis, Ph.D. iii Acknowledgements My greatest and sincerest gratitude goes towards my thesis advisor, professor, and mentor, Dr. Marta Concheiro-Guisan. You have educated me in more ways I thought possible and I am so thankful for all the experiences you have provided me with. As an educator you not only have taught me, but also have inspired me inside and outside the classroom.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (Revised and Updated)
    Recommended methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits: UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases, but any modification has to be validated before it is integrated into laboratory routines. Mention of names of firms and commercial products does not imply theendorsement of the United Nations. ST/NAR/48/REV.1 © United Nations, July 2020. All rights reserved, worldwide The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Services of the United Nations Office on Drugs and Crime (UNODC) (LSS, headed by Dr.
    [Show full text]
  • Synthetic Cannabinoids (60 Substances) A) Classical Cannabinoid
    Synthetic cannabinoids (60 substances) a) Classical cannabinoid OH H OH H O Common name Chemical name CAS number Molecular Formula HU-210 3-(1,1’-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1- Synonym: 112830-95-2 C H O hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol 25 38 3 11-Hydroxy-Δ-8-THC-DMH b) Nonclassical cannabinoids OH OH R2 R3 R4 R1 CAS Molecular Common name Chemical name R1 R2 R3 R4 number Formula rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methyloctan- 2- yl) CP-47,497 70434-82-1 C H O CH H H H phenol 21 34 2 3 rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methylheptan- 2- yl) CP-47,497-C6 - C H O H H H H phenol 20 32 2 CP-47,497-C8 rel-2- [(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methylnonan- 2- yl) 70434-92-3 C H O C H H H H Synonym: Cannabicyclohexanol phenol 22 36 2 2 5 CAS Molecular Common name Chemical name R1 R2 R3 R4 number Formula rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methyldecan- 2- yl) CP-47,497-C9 - C H O C H H H H phenol 23 38 2 3 7 rel-2- ((1 R,2 R,5 R)-5- hydroxy- 2- (3- hydroxypropyl)cyclohexyl)- 3-hydroxy CP-55,940 83003-12-7 C H O CH H H 5-(2- methyloctan- 2- yl)phenol 24 40 3 3 propyl rel-2- [(1 S,3 R)-3- hydroxy-5,5-dimethylcyclohexyl]- 5- (2- Dimethyl CP-47,497-C8 - C H O C H CH CH H methylnonan-2- yl)phenol 24 40 2 2 5 3 3 c) Aminoalkylindoles i) Naphthoylindoles 1' R R3' R2' O N CAS Molecular Common name Chemical name R1’ R2’ R3’ number Formula [1-[(1- methyl- 2- piperidinyl)methyl]- 1 H-indol- 3- yl]- 1- 1-methyl-2- AM-1220 137642-54-7 C H N O H H naphthalenyl-methanone 26 26 2 piperidinyl
    [Show full text]
  • Synthetic Cannabinoids Synthetic Cannabinoids-1
    Synthetic Cannabinoids-1 Synthetic Cannabinoids ™ (HEIA ) For the detection of JWH-018, JWH-073, AM-2201 & their major metabolites Homogeneous Enzyme Immunoassay (HEIA™) K2-3 K2-2 K2-1 Assay Specifications Sensitivity: 100% LC-MS/MS Confirmation Specificity: 87.5% Methodology: Homogeneous Enzyme Immunoassay Accuracy: 96.9% Positive Negative Cutoff: 10 ng/mL HEIA Positive 48 2* Calibrator: JWH-018 N-pentanoic acid (10 ng/mL) Negative 0 14 *2 discrepant specimens that screened negative were borderline negative at 10 ng/mL cutoff. AB-PINACA ADB-PINACA UR-144 XLR11 JWH-018 JWH-073 AM-2201 Immunalysis now offers three distinct Synthetic Cannabinoid Homogeneous Enzyme Immunoassays (HEIA™) Cross-Reactivity N/D = Cross-Reactivity < 0.05% for the detection of Synthetic Cannabinoids in urine. Our assays, geared towards the detection of JWH-018, JWH-073, AM-2201, UR-144, XLR11 and their metabolites, are now complemented by a NEW assay targeted Analyte Analyte Concentration JWH-018 N-pentanoic acid Cross-Reactivity at the next generation, AB-PINACA and ADB-PINACA compounds found in the current Spice or K2 products. (ng/mL) Equivalent (ng/mL) (%) Together, these assays detect Schedule I controlled substances and provide the most comprehensive screening JWH-018 N-pentanoic acid 10 10 100 tool for your automated chemistry analyzer. JWH-018 N-(5-hydroxypentyl) 15 10 67 JWH-018 4-hydroxyindole 135 10 7.4 JWH-018 5-hydroxyindole 40 10 25 AM-2201 N-(4-hydroxypentyl) 12 10 83 Liquid Stable, Ready to Use AM-2201 6-hydroxyindole 20 10 50 JWH-073 N-(4-hydroxybutyl)
    [Show full text]
  • Retrospective Identification of Synthetic Cannabinoids in Forensic Toxicology Casework Using Archived High Resolution Mass Spectrometry Data Author(S): Alex J
    The author(s) shown below used Federal funding provided by the U.S. Department of Justice to prepare the following resource: Document Title: Retrospective Identification of Synthetic Cannabinoids in Forensic Toxicology Casework using Archived High Resolution Mass Spectrometry Data Author(s): Alex J. Krotulski, Ph.D., Amanda L.A. Mohr, MSFS, D-ABFT-FT, Barry K. Logan, Ph.D., F-ABFT Document Number: 255668 Date Received: November 2020 Award Number: 2017-R2-CX-0021 This resource has not been published by the U.S. Department of Justice. This resource is being made publically available through the Office of Justice Programs’ National Criminal Justice Reference Service. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Title: Retrospective Identification of Synthetic Cannabinoids in Forensic Toxicology Casework using Archived High Resolution Mass Spectrometry Data Authors: Alex J Krotulski, PhD, Amanda LA Mohr, MSFS, D-ABFT-FT, and Barry K Logan, PhD, F-ABFT Organization: Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation, Willow Grove, PA, USA Award Number: 2017-R2-CX-0021 This resource was prepared by the author(s) using Federal funds provided by the U.S. Department of Justice. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Abstract Since 2008, synthetic cannabinoids have continued to proliferate and challenge the forensic science community due to rapid appearance and diverse chemistry.
    [Show full text]
  • How Present Synthetic Cannabinoids Can Help Predict Symptoms in the Future
    MOJ Toxicology Mini Review Open Access How present synthetic cannabinoids can help predict symptoms in the future Abstract Volume 2 Issue 1 - 2016 New synthetic cannabinoids appear regularly in the illicit drug market, often in response to Melinda Wilson-Hohler,1 Wael M Fathy,2 legal restrictions. These compounds are characterized by increasing binding affinities (Ki) 3 to CB1 and CB2 receptors. Increasing affinity to CB receptors can occur by substitution of a Ashraf Mozayani 1Consultant, The Forensic Sciences, USA halogen on the terminal position of the pentyl chain of the classical synthetic cannabinoids. 2Post-Doctoral Fellowship, Texas Southern University, USA & Fluorination of the aliphatic side chain of established cannabinoid agonists is a popular Toxicologist, Ministry of Justice, Egypt pathway of modifying existing active drugs and synthesizing novel drugs to increase 3Professor, Barbara Jordan-Mickey Leland School of Public potency. Biological impacts of these compounds that have been reported include seizures, Affairs, Texas Southern University, USA body temperature losses that may lead to cardiac distress, as well as cases reporting delirium and severe neural incapacities. These symptoms have been reported in case Correspondence: Ashraf Mozayani, Executive Director of reports with evidence that like their cannabinoid counterparts, these compounds distribute Forensic Science and Professor, Barbara Jordan-Mickey Leland post-mortem into a variety of tissues, especially adipose tissue. Researchers have detected School of Public Affairs, Texas Southern University, USA, and identified certain synthetic cannabinoid compounds on botanicals using a variety of Tel17132526556, Email [email protected] separation and detection systems such as GC-FID and GC-MS, as well as LC-MS/MS and NMR.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • Case: 1:18-Cr-00474-JRA; Zheng ECF Filed Indictment
    Case: 1:18-cr-00474-JRA Doc #: 1 Filed: 08/17/18 1 of 83. PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION UNITED STATES OF AMERICA, ) INDICTMENT Plaintiff, ~ JUDGE PO V. ~ CASE10; 18 CR ) Title 21, Sections 33l(a), FUJINO ZHENG, ) 333(b)(7), 35l(d), 841(a)(l), aka, GORDON JIN, ) (a)(2), (b)(l)(A), (b)(l)(C), (h), aka, MR. JIN, ) 843(c)(2)(A), 846, 848, 853, aka, GORDON ZHENG, ) 952(a), 959(a), 960(a)(l) and (3), aka, JINXINXIN, ) (b)(1 ), (b )(3), 963, and 970, aka, FU JING ZHENG, ) Title 18, Sections 1956(a)(2), (h), aka, DENG GAO, ) and 2, GUANGHUA ZHENG, ) United States Code aka, GUANG HUA ZHENG, ) ) Defendants. ) ) COUNT 1 (Conspiracy to Manufacture, Distribute, and Possess with the Intent to Distribute Controlled Substances and Controlled Substance Analogues Resulting in Death, 21 U.S.C. §§ 841(a)(l), (b)(l)(A), (b)(l)(C), all in violation of 21 U.S.C. § 846) The Grand Jury charges: 1. From on or about January 1, 2008 to the Present, the exact dates unknown to the Grand Jury, in the Northern District of Ohio, Eastern Division, the People's Republic of China, and elsewhere, Defendants FUJINO ZHENG, aka GORDON JIN, aka MR. JIN, aka GORDON ZHENG, aka JINXINXIN, aka FU JING ZHENG, aka DENG GAO; GUANGHUA ZHENG, aka GUANG HUA ZHENG; Guangfu Z.; Guifeng C.; Songyan J.; Longbao Z.; Qinghua Y., aka Jason Yen; Lynn X.; Leroy S.; (individuals whose names are known to the Grand Jury); Global United Biotechnology; Global United Holdings; Global Biotech, Inc.; Global Holdings, Inc.; Top Lab RC; Global RC; Golden Chemicals; Cambridge Chemicals; Wonda Science; OneChem; Case: 1:18-cr-00474-JRA Doc #: 1 Filed: 08/17/18 2 of 83.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]